Breaking News
Get 45% Off 0
🤖 Are you in? These 5 AI-picked stocks are up 15%+
Read article

Zacks Investment Research Zacks Investment Research

Zacks Investment Research's Opinion & Analysis.
Featured here: a complete archive of all posts and research produced by Zacks Investment Research, including current material.
4 Tobacco Stocks to Watch Amid Rising Popularity of RRPs By Zacks Investment Research - Sep 18, 2020

The Zacks Tobacco industry is likely to gain from the rising demand for low risk products such as vaping, e-cigarettes and heat-not-burn variants. These products, owing to their beneficial claims, are...

Bed Bath & Beyond Expands Google Cloud Deal on Online Demand By Zacks Investment Research - Sep 17, 2020

Bed Bath & Beyond Inc (NASDAQ:BBBY). BBBY has expanded its collaboration with Google (NASDAQ:GOOGL) Cloud, given the ongoing digital boom. In this regard, the company has signed a five-year deal...

Dow's Four-Day Run Ends as Stocks Dip Again By Zacks Investment Research - Sep 17, 2020

New Zacks Feature: ASK ALEXA Now call out a stock name or ticker. Alexa will give you its latest Zacks Rank and price. Also hear daily additions and deletions to your portfolio. For easy directions...

5 ETF Areas That Have Surged At Least 50% This Year By Zacks Investment Research - Sep 17, 2020

The year 2020 has been marked by the outbreak of the SARS (severe acute respiratory syndrome)-like coronavirus in late January. Due to the rapid spread of the virus, Wall Street snapped its longest...

Buy High-Yield General Mills (GIS) Stock Before Earnings? By Zacks Investment Research - Sep 17, 2020

General Mills (NYSE:GIS) GIS stock has lagged the market for years, as investors worry about the packaged food industry amid changing consumer habits. Yet GIS shares have outpaced the S&P 500 in...

3 Must-Have Nuveen Mutual Funds for Superlative Returns By Zacks Investment Research - Sep 17, 2020

Nuveen Investments, headquartered in Chicago, IL, was founded in 1898 by John Nuveen. The company seeks to provide financial services to its clients by using the multi-boutique structure. It provides...

Cloudflare (NET) Gains As Market Dips: What You Should Know By Zacks Investment Research - Sep 17, 2020

In the latest trading session, Cloudflare (NYSE:NET) closed at $36.10, marking a +0.56% move from the previous day. This move outpaced the S&P 500's daily loss of 0.84%. Elsewhere, the Dow lost...

NVIDIA Strikes an ARMs Deal to Take All the Chips By Zacks Investment Research - Sep 17, 2020

If NVIDIA NVDA gets regulatory approval to buy privately-held Arm Holdings from Softbank (OTC:SFTBY) Group, it will not only be the biggest semiconductor deal ever at $40 billion, it could be the most...

Moving Average Crossover Alert: MagnaChip Semiconductor By Zacks Investment Research - Sep 17, 2020

MagnaChip (NYSE:MX) Semiconductor Corporation MX is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front....

5 Hot Dirt-Cheap Growth Stocks to Buy Now By Zacks Investment Research - Sep 17, 2020

(0:45) - Finding Value Stocks With Growth(6:15) - Tracey’s Top Stock Picks(18:20) - Episode Roundup: MHO, MTH, SAH, STC, Podcast@Zacks.com Welcome to Episode #206 of the Value Investor...

Are Gold Mining ETFs More Sizzling Bets Than Bullion? By Zacks Investment Research - Sep 17, 2020

Gold has been great investment this year, thanks to an equity market crash at the start of the year and the resultant safe-haven rally. The coronavirus outbreak has kept global markets edgy. Gold...

What Makes Unicom (CHU) a New Buy Stock By Zacks Investment Research - Sep 17, 2020

Unicom (CHU) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of...

Corcept's Lead Drug Korlym Aids Growth, Heavy Reliance a Woe By Zacks Investment Research - Sep 16, 2020

On Sep 16, we issued an updated research report on Corcept Therapeutics (NASDAQ:CORT) Incorporated CORT.Corcept’s only marketed drug Korlym is approved for the once-daily oral treatment of...

Continue with Apple
Continue with Google
or
Sign up with Email